Infliximab (Remicade)

Handbook of Therapeutic Antibodies

Volumn 3, Issue , 2008, Pages 885-904

  Wiekowski, Maria ^a   Antoni, Christian ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adhesion molecules; Arthritis; Infliximab; Syndrome; Therapy

Indexed keywords

EID: 84889398795     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619740.ch34     Document Type: Chapter

References (68)

1. Knight, D.M., Trinh, H., Le, J., et al. (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30: 1443-1453.
2. Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.Y., Shealy, D., Wagner, C. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301: 418-426.
3. Scallon, B.J., Moore, M.A., Trinh, H., Knight, D.M., Ghrayeb, J. (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7: 251-259.
4. Siegel, S.A., Shealy, D.J., Nakada, M.T., Le, J., Woulfe, D.S., Probert, L., Kollias, G., Ghrayeb, J., Vilcek, J., Daddona, P.E. (1995) The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 7: 15-25.
5. Shen, C., Maerten, P., Geboes, K., Van Assche, G., Rutgeerts, P., Ceuppens, J.L. (2005) Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 115: 250-259.
6. Catrina, A.I., Trollmo, C., af Klint, E., Engstrom, M., Lampa, J., Hermansson, Y., Klareskog, L., Ulfgren, A.K. (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52: 61-72.
7. Gottlieb, A.B., Masud, S., Ramamurthi, R., Abdulghani, A., Romano, P., Chaudhari, U., Dooley, L.T., Fasanmade, A.A., Wagner, C.L. (2003) Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factoralpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 48: 68-75.
8. Cornillie, F., Shealy, D., D'Haens, G., Geboes, K., Van Assche, G., Ceuppens, J., Wagner, C., Schaible, T., Plevy, S.E., Targan, S.R., Rutgeerts, P. (2001) Infliximab induces potent antiinflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 15: 463-473.
9. St Clair, E.W., Wagner, C.L., Fasanmade, A.A., Wang, B., Schaible, T., Kavanaugh, A., Keystone, E.C. (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46: 1451-1459.
10. Markham, A., Lamb, H.M. (2000) Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59: 1341-1359.
11. Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F., Rachmilewitz, D., Wolf, D.C., Olson, A., Bao, W., Rutgeerts, P. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541-1549.
12. Lichtenstein, G.R., Yan, S., Bala, M., Hanauer, S. (2004) Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 99: 91-96.
13. Rutgeerts, P., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F., Rachmilewitz, D., Wolf, D.C., Olson, A., Bao, W., Hanauer, S.B. (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126: 402-413.
14. Lemann, M., Mary, J.Y., Duclos, B., Veyrac, M., Dupas, J.L., Delchier, J.C., Laharie, D., Moreau, J., Cadiot, G., Picon, L., Bourreille, A., Sobahni, I., Colombel, J.F. (2006) Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130: 1054-1061.
15. Sands, B.E., Anderson, F.H., Bernstein, C.N., et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876-885.
16. Lichtenstein, G.R., Yan, S., Bala, M., Blank, M., Sands, B.E. (2005) Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128: 862-869.
17. Lichtenstein, G.R., Feagan, B.G., Cohen, R.D., Salzberg, B.A., Diamond, R.H., Chen, D.M., Pritchard, M.L., Sandborn, W.J. (2006) Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4: 621-630.
18. Maini, R.N., Breedveld, F.C., Kalden, J.R., Smolen, J.S., Davis, D., Macfarlane, J.D., Antoni, C., Leeb, B., Elliott, M.J., Woody, J.N., Schaible, T.F., Feldmann, M. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552-1563.
19. Maini, R., St Clair, E.W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., Lipsky, P. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932-1939.
20. Lipsky, P.E., van der Heijde, D.M., St Clair, E.W., Furst, D.E., Breedveld, F.C., Kalden, J.R., Smolen, J.S., Weisman, M., Emery, P., Feldmann, M., Harriman, G. R., Maini, R.N. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594-1602.
21. Breedveld, F.C., Emery, P., Keystone, E., Patel, K., Furst, D.E., Kalden, J.R., St Clair, E.W., Weisman, M., Smolen, J., Lipsky, P.E., Maini, R.N. (2004) Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63: 149-155.
22. Maini, R.N., Breedveld, F.C., Kalden, J.R., Smolen, J.S., Furst, D., Weisman, M.H., St Clair, E.W., Keenan, G.F., van der Heijde, D., Marsters, P.A., Lipsky, P.E. (2004) Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50: 1051-1065.
23. Smolen, J.S., Han, C., Bala, M., Maini, R.N., Kalden, J.R., van der Heijde, D., Breedveld, F.C., Furst, D.E., Lipsky, P.E. (2005) Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52: 1020-1030.
24. Ritchlin, C.T., Schwarz, E.M., O'Keefe, R.J., Looney, R.J. (2004) RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. J Musculoskelet Neuronal Interact 4: 276-284.
25. St Clair, E.W., van der Heijde, D.M., Smolen, J.S., Maini, R.N., Bathon, J.M., Emery, P., Keystone, E., Schiff, M., Kalden, J.R., Wang, B., Dewoody, K., Weiss, R., Baker, D. (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50: 3432-3443.
26. Smolen, J.S., Van Der Heijde, D.M., St Clair, E.W., Emery, P., Bathon, J.M., Keystone, E., Maini, R.N., Kalden, J.R., Schiff, M., Baker, D., Han, C., Han, J., Bala, M. (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54: 702-710.
27. Taylor, P.C., Steuer, A., Gruber, J., Cosgrove, D.O., Blomley, M.J., Marsters, P.A., Wagner, C.L., McClinton, C., Maini, R.N. (2004) Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebocontrolled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 50: 1107-1116.
28. Hyrich, K.L., Symmons, D.P., Watson, K.D., Silman, A.J. (2006) Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54: 1786-1794.
29. Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., Gromnica-Ihle, E., Kellner, H., Krause, A., Schneider, M., Sorensen, H., Zeidler, H., Thriene, W., Sieper, J. (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359: 1187-1193.
30. Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Burmester, G., Golder, W., Gromnica-Ihle, E., Kellner, H., Schneider, M., Sorensen, H., Zeidler, H., Reddig, J., Sieper, J. (2003) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebocontrolled trial. Arthritis Rheum 48: 2224-2233.
31. Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Burmester, G., Gromnica-Ihle, E., Kellner, H., Schneider, M., Sorensen, H., Zeidler, H., Sieper, J. (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64: 229-234.
32. Sieper, J., Baraliakos, X., Listing, J., Brandt, J., Haibel, H., Rudwaleit, M., Braun, J. (2005) Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 44: 1525-1530.
33. Baraliakos, X., Listing, J., Rudwaleit, M., Brandt, J., Sieper, J., Braun, J. (2005) Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 64: 1462-1466.
34. Braun, J., Baraliakos, X., Brandt, J., Listing, J., Zink, A., Alten, R., Burmester, G., Gromnica-Ihle, E., Kellner, H., Schneider, M., Sorensen, H., Zeidler, H., Sieper, J. (2005) Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 44: 670-676.
35. Baraliakos, X., Listing, J., Brandt, J., Zink, A., Alten, R., Burmester, G., Gromnica-Ihle, E., Kellner, H., Schneider, M., Sorensen, H., Zeidler, H., Rudwaleit, M., Sieper, J., Braun, J. (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7: R439-R444
36. van der Heijde, D., Dijkmans, B., Geusens, P., Sieper, J., DeWoody, K., Williamson, P., Braun, J. (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52: 582-591.
37. van Kuijk, A.W., Reinders-Blankert, P., Smeets, T.J., Dijkmans, B.A., Tak, P.P. (2006) Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for therapy. Ann Rheum Dis. (in press).
38. Olaniran, A.K., et al. (1996) Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch Dermatol Res 288(8): 421-425.
39. Lizzul, P.F., Aphale, A., Malaviya, R., Sun, Y., Masud, S., Dombrovskiy, V., Gottlieb, A.B. (2005) Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 124: 1275-1283.
40. Danning, C.L., Illei, G.G., Hitchon, C., Greer, M.R., Boumpas, D.T., McInnes, I.B. (2000) Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 43(6): 1244-1256.
41. Ogilvie, A.L., Antoni, C., Dechant, C., Manger, B., Kalden, J.R., Schuler, G., Luftl, M. (2001) Treatment of psoriatic arthritis with antitumour necrosis factoralpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 144: 587-589.
42. Antoni, C., Dechant, C., Hanns-Martin Lorenz, P.D., Wendler, J., Ogilvie, A., Lueftl, M., Kalden-Nemeth, D., Kalden, J.R., Manger, B. (2002) Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 47: 506-512.
43. Antoni, C.E., Kavanaugh, A., Kirkham, B., et al. (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52: 1227-1236.
44. Antoni, C., Krueger, G.G., de Vlam, K., Birbara, C., Beutler, A., Guzzo, C., Zhou, B., Dooley, L.T., Kavanaugh, A. (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64: 1150-1157.
45. Kavanaugh, A., Antoni, C.E., Gladman, D., Wassenberg, S., Zhou, B., Beutler, A., Keenan, G., Burmester, G., Furst, D.E., Weisman, M.H., Kalden, J.R., Smolen, J., van der Heijde D. (2006) The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 65: 1038-1043.
46. Mastroianni, A., et al. (2005) Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 153(3): 531-536.
47. Canete, J.D., Pablos, J.L., Sanmarti, R., Mallofre, C., Marsal, S., Maymo, J., Gratacos, J., Mezquita, J., Mezquita, C., Cid, M.C. (2004) Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 50: 1636-1641.
48. Gottlieb, A.B., Evans, R., Li, S., Dooley, L.T., Guzzo, C.A., Baker, D., Bala, M., Marano, C.W., Menter, A. (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebocontrolled trial. J Am Acad Dermatol 51: 534-542.
49. Feldman, S.R., Gordon, K.B., Bala, M., Evans, R., Li, S., Dooley, L.T., Guzzo, C., Patel, K., Menter, A., Gottlieb, A.B. (2005) Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 152: 954-960.
50. Reich, K., Nestle, F.O., Papp, K., Ortonne, J.P., Evans, R., Guzzo, C., Li, S., Dooley, L.T., Griffiths, C.E. (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366: 1367-1374.
51. Rutgeerts, P., Sandborn, W.J., Feagan, B.G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S.B., Lichtenstein, G.R., de Villiers, W.J., Present, D., Sands, B.E., Colombel, J.F. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462-2476.
52. Jarnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlen, P., Granno, C., Vilien, M., Strom, M., Danielsson, A., Verbaan, H., Hellstrom, P.M., Magnuson, A., Curman, B. (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128: 1805-1811.
53. Westhovens, R., Yocum, D., Han, J., Berman, A., Strusberg, I., Geusens, P., Rahman, M.U. (2006) The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54: 1075-1086.
54. Askling, J., Fored, C.M., Brandt, L., Baecklund, E., Bertilsson, L., Coster, L., Geborek, P., Jacobsson, L.T., Lindblad, S., Lysholm, J., Rantapaa-Dahlqvist, S., Saxne, T., Romanus, V., Klareskog, L., Feltelius, N. (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52: 1986-1992.
55. Carmona, L., Gomez-Reino, J.J., Rodriguez-Valverde, V., Montero, D., Pascual-Gomez, E., Mola, E.M., Carreno, L., Figueroa, M. (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52: 1766-1772.
56. Hanauer, S.B., Wagner, C.L., Bala, M., Mayer, L., Travers, S., Diamond, R.H., Olson, A., Bao, W., Rutgeerts, P. (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2: 542-553.
57. Baert, F., Noman, M., Vermeire, S., Van Assche, G., Carbonez, A., Rutgeerts, P. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601-608.
58. Sellam, J., Allanore, Y., Batteux, F., Deslandre, C.J., Weill, B., Kahan, A. (2005) Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate. Joint Bone Spine 72: 48-52.
59. Eriksson, C., Engstrand, S., Sundqvist, K.G., Rantapaa-Dahlqvist, S. (2005) Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 64: 403-407.
60. Nancey, S., Blanvillain, E., Parmentier, B., Flourie, B., Bayet, C., Bienvenu, J., Fabien, N. (2005) Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-doublestranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis 11: 986-991.
61. Jonsdottir, T., Forslid, J., van Vollenhoven, A., Harju, A., Brannemark, S., Klareskog, L., van Vollenhoven, R.F. (2004) Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 63: 1075-1078.
62. Mohan, N., Edwards, E.T., Cupps, T.R., Oliverio, P.J., Sandberg, G., Crayton, H., Richert, J.R., Siegel, J.N. (2001) Demyelination occurring during antitumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44: 2862-2869.
63. Geborek, P., Bladstrom, A., Turesson, C., Gulfe, A., Petersson, I.F., Saxne, T., Olsson, H., Jacobsson, L.T. (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64: 699-703.
64. Wolfe, F., Michaud, K. (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50: 1740-1751.
65. Kandiel, A., Fraser, A.G., Korelitz, B.I., Brensinger, C., Lewis, J.D. (2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54: 1121-1125.
66. Chung, E.S., Packer, M., Lo, K.H., Fasanmade, A.A., Willerson, J.T. (2003) Randomized, double-blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107: 3133-3140.
67. Jacobsson, L.T., Turesson, C., Gulfe, A., Kapetanovic, M.C., Petersson, I.F., Saxne, T., Geborek, P. (2005) Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32: 1213-1218.
68. Katz, J.A., Antoni, C., Keenan, G.F., Smith, D.E., Jacobs, S.J., Lichtenstein, G.R. (2004) Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 99: 2385-2392.